345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study.
Saved in:
| Title: | 345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study. |
|---|---|
| Authors: | Lemech, C.1 (AUTHOR), Sun, Y.2 (AUTHOR), Nagrial, A.3 (AUTHOR), Wu, X.4 (AUTHOR), Morris, M.5 (AUTHOR), Ning, F.6 (AUTHOR), Yang, J.7 (AUTHOR), Pan, Y.8 (AUTHOR), Cai, J.9 (AUTHOR), Lu, P.10 (AUTHOR), Zhang, T.11 (AUTHOR), Qiu, F.12 (AUTHOR), Hu, C.13 (AUTHOR), Zhang, M.14 (AUTHOR), Liu, Z.15 (AUTHOR), Han, G.16 (AUTHOR), Nie, J.17 (AUTHOR), Teng, C.1 (AUTHOR), Zhou, H.18 (AUTHOR), Day, D.19 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS360-S360. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.293 |
